Temozolomide’s effect on low-grade gliomas

Low-grade gliomas tend to vary quite a bit, from a biological standpoint and how they respond to treatment. 

In order to better understand and optimize the use of temozolomide in a clinical setting, UCSF’s Dr. Joseph Costello will study how this drug affects the genetic makeup of lower grade gliomas over time. 

Based on preliminary data, the study expects to identify mutations that arise during tumor evolution and for which novel targeted therapies exist, but have not yet been tested in this patient group.


Share |

Join us in our fight for a cure!